Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 03, 2021 07:30 ET | Source: Purple Biotech Ltd.

Purple Biotech to Present at the Jefferies London Healthcare Conference

REHOVOT, Israel, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" ", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and...
October 26, 2021 08:27 ET | Source: Purple Biotech Ltd.

Purple Biotech Expands Research Collaboration in Immuno-Oncology in Combination with NT219

Collaboration to Study NT219 in Combination with anti-CTLA4 and anti-PD1/PDL1 Antibodies REHOVOT, Israel, Oct. 26, 2021 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech", or the...
October 22, 2021 06:00 ET | Source: Purple Biotech Ltd.

Purple Biotech Announces Publication in Nature Cancer Demonstrating Mechanisms Behind Cancer Cell Persistence Frequency and Potential of NT219 to Reduce Therapeutic Resistance

Research Highlights Underlying the IRS1 Phosphorylation Status as a Memory Mechanism that Modulates Cellular Non-Genetic Resistance to Drug Therapy NT219, which Targets IRS, Shown to be Highly...
September 13, 2021 07:00 ET | Source: Purple Biotech Ltd.

Purple Biotech to Present Overview of Ongoing Phase 1b/2 Clinical Trial of CM24 for Treatment of Multiple Advanced Cancers at ESMO 2021 and Provides Clinical Update

One Advanced Pancreatic Cancer Patient Demonstrated a Partial Response in First Dose Cohort in Combination with Nivolumab Patient Enrollment in Second Dose Cohort Complete Study Expanding...
August 05, 2021 08:30 ET | Source: Purple Biotech Ltd.

Purple Biotech Provides Corporate Update and Reports First Half 2021 Financial Results

REHOVOT, Israel, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech”, or the “Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and...
June 04, 2021 08:00 ET | Source: Purple Biotech Ltd.

Purple Biotech Presents New Clinical Data from NT219 at the 2021 ASCO Annual Meeting

Partial Response Observed in a Patient with Refractory Gastroesophageal Junction Cancer REHOVOT, Israel, June 04, 2021 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech", or the...
May 26, 2021 07:38 ET | Source: Purple Biotech Ltd.

Purple Biotech to Present at the Jefferies Virtual Healthcare Conference

REHOVOT, Israel, May 26, 2021 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and...
May 20, 2021 07:00 ET | Source: Purple Biotech Ltd.

Purple Biotech to Present New Clinical Data from NT219 at the 2021 ASCO Annual Meeting

Initial Data from Ongoing Phase 1/2 Clinical Trial of NT219 in Adults with Advanced Solid Tumors and Head and Neck Cancer to be Highlighted REHOVOT, Israel, May 20, 2021 (GLOBE NEWSWIRE) -- ...
May 19, 2021 07:00 ET | Source: Purple Biotech Ltd.

Purple Biotech Appoints Seasoned Biopharmaceutical Industry Executive Suzana Nahum-Zilberberg to Board of Directors

REHOVOT, Israel, May 19, 2021 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" ", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and...
April 23, 2021 08:00 ET | Source: Purple Biotech Ltd.

Purple Biotech Announces Dosing of First Patient in Phase 1b/2 Clinical Trial of CM24 in Advanced Cancer Patients

Preliminary Data from First Part of Study Anticipated in Second Half of 2021 REHOVOT, Israel, April 23, 2021 (GLOBE NEWSWIRE) -- Purple Biotech (Nasdaq/TASE: PPBT), a clinical-stage company...